Sustained spinal cord compression: part II: effect of methylprednisolone on regional blood flow and recovery of somatosensory evoked potentials.

Abstract

BACKGROUND:

The efficacy of methylprednisolone in the treatment of traumatic spinal cord injury is controversial. We examined the effect of methylprednisolone on regional spinal cord blood flow and attempted to determine whether recovery of electrophysiological function is dependent on reperfusion, either during sustained spinal cord compression or after decompression.

METHODS:

The effects of methylprednisolone therapy on recovery of somatosensory evoked potentials and on spinal cord blood flow were examined in a canine model of dynamic spinal cord compression. Methylprednisolone (30 mg/kg intravenous loading dose followed by 5.4 mg/kg/hr intravenous infusion) or saline solution was administered to thirty-six beagles (eighteen in each group) five minutes after cessation of dynamic spinal cord compression and loss of all somatosensory evoked potentials. After ninety minutes of sustained compression, the spinal cords were decompressed. Somatosensory evoked potentials and spinal cord blood flow were evaluated throughout the period of sustained compression and for three hours after decompression.

RESULTS:

Seven dogs treated with methylprednisolone and none treated with saline solution recovered measurable somatosensory evoked potentials during sustained compression. After decompression, three more dogs treated with methylprednisolone and seven dogs treated with saline solution recovered somatosensory evoked potentials. Four dogs treated with methylprednisolone lost their previously measurable somatosensory evoked potentials. In the methylprednisolone group, spinal cord blood flow was significantly higher (p < 0.05) in the dogs that had recovered somatosensory evoked potentials than it was in the dogs that had not. Reperfusion blood flow was significantly higher (p < 0.05) in the saline-solution group than it was in the methylprednisolone group. Spinal cord blood flow in the saline-solution group returned to baseline levels within five minutes after decompression. It did not return to baseline levels in the dogs treated with methylprednisolone.

CONCLUSIONS:

The methylprednisolone administered in this study did not provide a large or significant lasting benefit with regard to neurological preservation or restoration. Methylprednisolone may reduce regional spinal cord blood flow through mechanisms affecting normal autoregulatory blood-flow function.

• Authors: Gregory D Carlson, Carey D Gorden, Shigenobu Nakazawa, Eiji Wada, Jeremy S Smith, Joseph C LaManna
• Journal: The Journal of bone and joint surgery. American volume (J Bone Joint Surg Am) Vol. 85 Issue 1 Pg. 95-101 (Jan 2003) ISSN: 0021-9355 [Print] United States
• PMID: 12533578 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)

Chemical References

• Neuroprotective Agents
• Methylprednisolone

Topics

• Animals
• Biomechanical Phenomena
• Disease Models, Animal
• Dogs
• Evoked Potentials, Somatosensory (drug effects, physiology)
• Methylprednisolone (pharmacology, therapeutic use)
• Neuroprotective Agents (pharmacology, therapeutic use)
• Recovery of Function (drug effects, physiology)
• Regional Blood Flow (drug effects, physiology)
• Spinal Cord (drug effects, physiopathology)
• Spinal Cord Compression (complications, drug therapy, physiopathology)
• Spinal Cord Injuries (drug therapy, etiology, physiopathology)
• Time Factors
• Trauma Severity Indices